-
Eye Catching Stocks: Sony Corp (ADR) (NYSE:SNE), Biocept (NASDAQ:BIOC), Hewlett-Packard Company (NYSE:HPQ), ReachLocal (NASDAQ:RLOC), Yahoo! Inc. (NASDAQ:YHOO)
On Thursday shares of Sony Corp (ADR) (NYSE:SNE) closed at $27.85. Company’s sales growth for last 5 years was 0.10%. Sony Corp (ADR) (NYSE:SNE) has announced a new Xperia smartphone, the J1 Compact (D5788) in its domestic market. The Sony Xperia J1 Compact is the company’s first SIM free smartphone that will allow buyers to…
-
Investor’s Choice: Biocept (NASDAQ:BIOC), Charter Communications (NASDAQ:CHTR), Cisco Systems (NASDAQ:CSCO), Stepan Company (NYSE:SCL), Ericsson (NASDAQ:ERIC)
On 10 March 2015, Biocept, Inc. (NASDAQ:BIOC) announced the launch of its EGFR mutation detection testing utilizing a patient’s blood-based liquid biopsy. This innovative diagnostic has the potential to help physicians identify which of their patients may be receptive to certain non-small cell lung cancer treatments. On Thursday shares of Biocept, Inc. (NASDAQ:BIOC) closed at…
-
Notable Moves: CafePress Inc. (NASDAQ:PRSS), JA Solar Holdings Co., (NASDAQ:JASO), CGI Group (NYSE:GIB), Biocept (NASDAQ:BIOC), China Telecom Corp. (NYSE:CHA)
On March 6, 2015, CafePress Inc. (NASDAQ: PRSS) completed the closing of the previously announced sale of its businesses that engage in providing personalized apparel and merchandise for groups and organizations through its e-commerce websites (or, the “Groups Business”), pursuant to the asset purchase agreement (the “Asset Purchase Agreement”) with Logo Sportswear Inc. (“Logo Sportswear”),…
-
5 Stock in Different Moves: Conns Inc. (NASDAQ:CONN), Biocept (NASDAQ:BIOC), Transmontaigne Partners L.P. (NYSE:TLP), Global Power Equipment (NYSE:GLPW), Media General (NYSE:MEG)
Conn’s, Inc. (NASDAQ:CONN), announced it will host a conference call on March 31, 2015 to discuss its fourth-quarter and full year fiscal 2015 financial resultsOn Wednesday shares of Conns Inc. (NASDAQ:CONN) closed at $27.50. Company’s sales growth for last 5 years was 4.30% and EPS growth for next 5 years is recorded as 18.50%. Biocept,…
-
5 Stocks: Biocept (NASDAQ:BIOC), E. I. du Pont de Nemours and Company (NYSE:DD), Bank of America (NYSE:BAC), HopFed Bancorp (NASDAQ:HFBC), Aetna (NYSE:AET)
Biocept Inc (NASDAQ:BIOC) announced the launch of its EGFR mutation detection testing utilizing a patient’s blood-based liquid biopsy. This innovative diagnostic has the potential to help physicians identify which of their patients may be receptive to certain non-small cell lung cancer treatments. On Tuesday shares of Biocept, Inc. (NASDAQ:BIOC) closed at $3.38. Company’s EPS growth…
-
Stocks Buzz: ArQule Inc. (NASDAQ:ARQL), Biocept (NASDAQ:BIOC), Steven Madden, (NASDAQ:SHOO), Telefonica S.A. (ADR) (NYSE:TEF), Legg Mason Inc. (NYSE:LM)
ArQule, Inc. (NASDAQ:ARQL) announced that it will report its financial results for the fiscal 2014 year-end and fourth quarter on Wednesday, March 4, 2015 at 7:00 a.m. eastern time. On Friday shares of ArQule Inc. (NASDAQ:ARQL) closed at $1.88. Company’s sales growth for last 5 years was 2.40% and EPS growth for next 5 years…
-
Why Investors Are Watching: Biocept (NASDAQ:BIOC), NorthStar Realty Finance Corp. (NYSE:NRF), Sharps Compliance Corp. (NASDAQ:SMED), Tesla Motors (NASDAQ:TSLA), Baidu Inc (NASDAQ:BIDU)
Biocept, Inc. (Nasdaq:BIOC) announced that the Company will issue its financial results for the fourth quarter of 2014 on Monday, March 9, 2015, after the close of the market, and will hold a conference call on this day at 4:30 p.m. ET to discuss the financial results and provide a company update. On Thursday shares…
-
Stocks News Alert: Cytori Therapeutics (NASDAQ:CYTX), Biocept (NASDAQ:BIOC), Synacor (NASDAQ:SYNC), STAG Industrial (NYSE:STAG), Microsoft Corporation (NASDAQ:MSFT)
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced that it received approval from FDA to expand the number of Scleroderma clinical trial sites from 12 to 20 centers in the United States. The STAR study is an 80 patient pivotal clinical trial approved by FDA in January 2015 to study the effects of Cytori’s lead drug ECCS-50 for…